அர்ஜுன் வசந்த பாலார் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அர்ஜுன் வசந்த பாலார். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அர்ஜுன் வசந்த பாலார் Today - Breaking & Trending Today

Survival Boost in Bladder Cancer With Antibody-Drug Conjugate

email article
The antibody-drug conjugate (ADC) enfortumab vedotin significantly improved overall survival (OS) in patients with advanced, previously treated bladder cancer, a large randomized trial showed.
Median OS improved from about 9 months with standard chemotherapy to almost 13 months with enfortumab vedotin-ejfv (Padcev). Median progression-free survival also improved significantly with the ADC, from 3.71 to 5.55 months.
The incidence of treatment-related adverse events (TRAEs) was similar between treatment groups, including grade ≥3 TRAEs, reported Thomas Powles, MD, of Barts Cancer Center and Queen Mary University in London, during the virtual Genitourinary Cancers Symposium (GuCS). The results were published simultaneously in the
Enfortumab vedotin is the first drug beyond chemotherapy and immune therapy to show a significant survival advantage in previously treated advanced urothelial cancer, said Powles. This is a big step in the right dire ....

New York , United States , City Of , United Kingdom , Arjun Vasant Balar , Charles Bankhead , Thomas Powles , Langone Health , Queen Mary University , Barts Cancer Center , Perlmutter Cancer Center , Genitourinary Cancers Symposium , New England Journal , Medpage Today , Carcinoma Of Bladder , Malignant Tumor Of Urinary Bladder , Mass Of Body Structure , Neoplastic Disease , Malignant Adenomatous Neoplasm , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , அர்ஜுன் வசந்த பாலார் , சார்லஸ் வங்கித் தலை , லன்கொனே ஆரோக்கியம் ,

Sacituzumab Govitecan – Another Antibody Drug Conjugate Carving out a Path in Genitourinary Oncology

Sacituzumab Govitecan – Another Antibody Drug Conjugate Carving out a Path in Genitourinary Oncology
Published 01 February 2021
I have previously discussed the use of antibody-drug conjugates for selective tumor cell intensification of urothelial carcinoma therapy in a Urotoday Clinical Trials Portal article.
1 Similarly, I’ve also focused on enfortumab vedotin before, and enfortumab vedotin is now FDA approved on the accelerated pathway for patients with locally advanced or metastatic urothelial carcinoma in the post-platinum chemotherapy and post-PD-(L1) antibody therapy setting.
2 Yet, even as new data continues to emerge on the use of enfortumab vedotin in various settings, we should take time to evaluate the development of other promising antibody-drug conjugates. ....

United States , Fred Hutchinson Cancer Research Center , University Of Washington , Julio Hajdenberg , Arjun Vasant Balar , Scottt Tagawa , Aditya Bardia , Daniel Peter , Saby George , Philip James Saylor , Evan Yu , Manojkumar Bupathi , Aliciak Morgans , Arash Rezazadeh , Rohitk Jain , Bishoy Morris Faltas , European Society Of Medical Oncology , American Society Of Clinical Oncology , Clinical Research Division , Clinical Research Service , Seattle Cancer Care Alliance , Clinical Research , Fred Hutchinson Cancer Research Consortium , University Of Washington School Medicine , Division Of Oncology , Department Of Medicine ,